8:00 am

Registration & Coffee

9:00 am Chair’s Opening Remark

9:00 am Chairman’s Opening Remarks

REVIEWING RECENT DEVELOPMENTS IN FOOD ALLERGY DRUGS TO ERADICATE THE FOOD ALLERGY “EPIDEMIC”

Synopsis

As the prevalence of food allergies continues to rise, we’re seeing an increase in investments to create innovative therapies that address the underlying causative factors of food allergies, rather than simply treating the symptoms.

9:15 am Angany’s Unique Peanut Allergy Vaccine: Aiming to Overcome Peanut Allergy via Active Immunotherapy

  • Guy Tropper Co-founder and Senior Vice President, Angany

Synopsis

  • Sharing allergen-bearing Ebioparticles™ mimicking viruses: why and how
  • Understanding the safety, efficacy and convenience of vaccinal approach: helping patients beyond the desensitization paradigm
  • Considering advantages and ethics of green biomanufacturing treating, curing, or preventing allergy?
  • The future: what Angany’s approaches to cancer immunotherapy and allergy immunotherapy have in common

9:45 am Oral Mucosal Therapy (OMIT): Continues to Meet Safety Goals

  • William Reisacher Professor of Otolaryngology & Director of Allergy Services, Intrommune and Weill Cornell, Cornell University

Synopsis

  • Determining the maximum tolerated dose omit
  • Different mucosal areas within the oral cavity have different properties
  • Understanding several methods available to deliver allergens and other agents to the oral cavity mucosa
  • Exposure of food and airborne allergens to the oral mucosa has been shown to produce robust desensitization over time

10:15 am Sublingual Immunotherapy (SLIT) as a Safe & Tolerable Approach for Long-Term Food Allergy Therapy

Synopsis

  • Understanding sublingual immunotherapy (SLIT) for food allergy and its effects on tolerance
  • How to approach defining and meeting clinical endpoints
  • Taking into considerations variability within and across patient populations
  • How could this approach be extended beyond peanuts to other allergens?

10:45 am Session Reserved for Buhlmann Diagnostics Corporation

11:00 am

Morning Refreshments & Speed Networking

12:00 pm Breaking the Microbiome Stigma to Develop Smarter and Safer Therapeutic Approaches

  • Nikole Kimes Founder & Chief Executive Officer, Siolta Therapeutics

Synopsis

  • The gut microbiome and atopic disease
  • Assessing the effectiveness of gut microbiota in combating food allergy
  • Opportunities in using microbial signatures to develop diagnostic tools

12:30 pm Safely Targeting T Cells to Induce Durable Modulation of Allergen- Specific Immune Responses in Food Allergy

Synopsis

  • The central role T cells play in regulating allergic reactivity
  • How to target allergen-specific T cells in vivo, precisely and efficiently
  • The potential to go beyond desensitization with peptide immunotherapy and aim for long term tolerance

1:00 pm

Lunch & Networking

2:00 pm Developing Antibody-Based Approaches to Reduce Downstream Allergenic Responses

Synopsis

  • Re-engineering Ig-E antibodies to directly block the molecules in underlying disease
  • Potential future use of monoclonal antibody therapeutics to address specific allergies with high affinity
  • Effects of addressing key allergens directly on safety and mechanism of action

2:30 pm Taking the Next Step from Food Allergy Desensitization Towards Prevention: Striving to Upgrade Consumer Health

  • Richard Insel Global Head, Healthy Baby Initiative, World Without Disease Accelerator, Janssen R&D

Synopsis

  • Understanding the association between food allergy and other atopic diseases: impact on paediatric development
  • Bridging the gap between nutritional therapy and food allergy prevention to redirect the immune system
  • Discussing pre-clinical and clinical challenges in safety and efficacy associated with developing food allergy consumer products

ADDRESSING THE UNMET NEED IN FOOD ALLERGY TRANSLATION TO IMPROVE PREVENTION, TREATMENT & MANAGEMENT OF FOOD ALLERGIES

Synopsis

It is clear that the diagnostic landscape for identifying food allergies at this time is quite constrained. While oral challenges are useful, they can also be risky and cause serious responses, which endanger safety and decrease patients’ desire to participate in studies that employ that diagnosis.

3:00 pm The Missing Piece in Food Allergy Diagnostics: to Increase Test Sensitivity & Provide a More Detailed Patient-Tailored Risk Profile

Synopsis

  • Increasing accuracy of allergy diagnosis without the need for a food challenge
  • Developing a scalable diagnostic fit for hassle free patient use
  • Potential of molecular diagnostics
  • Linking the diagnostic tool with overall drug development – measuring endpoints and baselines

3:30 pm

AFTERNOON BREAK & NETWORKING

4:00 pm Panel Discussion: Recognizing Novel & Emerging Biomarkers of Significance to Help Identify Populations for Clinical Trial Studies, Monitor Therapeutic Response & Identify Side Effects

  • William Reisacher Professor of Otolaryngology & Director of Allergy Services, Intrommune and Weill Cornell, Cornell University
  • Kari Brown Senior Medical Director, Aimmune Therapeutics
  • Nikole Kimes Founder & Chief Executive Officer, Siolta Therapeutics
  • Soheila Maleki Research Scientist, U.S. Department of Agriculture

Synopsis

  • How do we reduce the need for DBPCFC (double-blind placebo-controlled food challenge) for clinical assessment?
  • Developing biomarkers that are informative of key clinical parameters of food allergy, including threshold of reactivity, risk of severe reactions, probability of natural resolution, and probability of successful treatment response to immunotherapy
  • How do we bring about the shift to test the utility of novel biomarkers for use in guiding clinical care rather than a research tool?

5:00 pm Chairman’s Closing Remarks

5:15 pm Close of Day 1